Search 

AnGes is a commercial-stage biopharmaceutical company that focuses on the development and commercialization of gene-based medicines including gene therapy, oligonucleotide drugs and DNA vaccines.
The company's lead product is Collategene for critical limb ischemia (CLI), the severest form of peripheral arterial disease (PAD), for which obtained conditional approval in Japan on March 2019. Collategene is a gene therapy product utilizing therapeutic angiogenesis by hepatocyte growth factor (HGF) gene expression. Our second project is NF-kB decoy oligonucleotide, for which a phase 1b study for low back pain commenced in February 2018 in the US. AnGes also conducting a phase I/II study for DNA vaccine for the treatment of hypertension.
We are also developing a DNA vaccine for COVID-19 which we plan to start Phase 3 from early next year.

GEMSEKI facilitates partnering and licensing activities by using web platform and actively reaching out to potential licensees effectively.
GEMSEKI launched in Oct 2017 as a subsidiary of SNBL a public Japanese company (Tokyo Stock Exchange 2395:JP)
We are looking for assets for in-licensing opportunities of our clients.
Also we have several Japanese and non-Japanese assets in oncology, infection, RA/OA , pain and rheumatoid arthritis available for out-licensing.

PHASTAR is a global biometrics CRO offering statistical consulting, clinical trial reporting, data management and data science services by providing expert consultants and managing and delivering in-house projects, FSP-style arrangements and preferred partnerships.

Our number one priority is ensuring on time, quality work: every project undertaken is supervised on methodology and utilizes internal processes designed to guarantee optimal quality, inspired by 3,700 years accumulated technical experience across the company.

PHASTAR is headquartered in London (UK) and North Carolina (US) and has 12 offices across five continents.